Association of rare MSH6 variants with familial breast cancer Marijke WasielewskiMuhammad RiazMieke Schutte Preclinical study 19 November 2009 Pages: 315 - 320
A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action Wei WangElizabeth R. RayburnRuiwen Zhang Preclinical study 21 November 2009 Pages: 321 - 331
Dietary energy availability affects primary and metastatic breast cancer and metformin efficacy Kathryn N. PhoenixFrank VumbacaKevin P. Claffey Preclinical study 22 November 2009 Pages: 333 - 344
ETAR antagonist ZD4054 exhibits additive effects with aromatase inhibitors and fulvestrant in breast cancer therapy, and improves in vivo efficacy of anastrozole Martin SmollichMartin GöttePia Wülfing Preclinical study 27 November 2009 Pages: 345 - 357
UHRF1 is associated with epigenetic silencing of BRCA1 in sporadic breast cancer Wei JinLi ChenZhi-ming Shao Preclinical study 27 November 2009 Pages: 359 - 373
RACK1 promotes breast carcinoma proliferation and invasion/metastasis in vitro and in vivo Xi-Xi CaoJing-Da XuXiu-Ping Liu Preclinical study 28 November 2009 Pages: 375 - 386
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells Amelia D’AlessioAntonella De LucaNicola Normanno Preclinical study 28 November 2009 Pages: 387 - 396
Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ M. SharmaA. H. BeckR. B. West Preclinical study 01 December 2009 Pages: 397 - 404
Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice Reginald M. GorczynskiZhiqi ChenJulia Behnke Preclinical study 02 December 2009 Pages: 405 - 415
Physical activity levels after treatment for breast cancer: one-year follow-up Nele DevoogdtMarijke Van KampenMarie-Rose Christiaens Clinical trial 27 June 2010 Pages: 417 - 425
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer Christopher LoboGilberto LopesStefan Glück Clinical trial 29 June 2010 Pages: 427 - 435
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial Isabell WitzelSibylle LoiblVolkmar Müller Clinical trial 10 July 2010 Pages: 437 - 445
Corticosteroid treatment and timing of surgery in idiopathic granulomatous mastitis confusing with breast carcinoma Fazilet ErozgenYeliz E. ErsoyRafet Kaplan Clinical trial 13 July 2010 Pages: 447 - 452
Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2) Kathleen I. PritchardJanusz RolskiPatrick Neven Clinical trial 15 July 2010 Pages: 453 - 461
Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer H. WildiersC. FontaineR. Paridaens Clinical trial 22 July 2010 Pages: 463 - 469
A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer Denise YardleyHoward Burris IIIJohn Hainsworth Clinical trial 24 July 2010 Pages: 471 - 475
Depressive symptoms among young breast cancer survivors: the importance of reproductive concerns Jessica R. GormanVanessa L. MalcarneJohn P. Pierce Epidemiology 04 February 2010 Pages: 477 - 485
BRCA2 N372H polymorphism and breast cancer susceptibility: a meta-analysis involving 44,903 subjects Li-Xin QiuLei YaoXi-Chun Hu Epidemiology 05 February 2010 Pages: 487 - 490
Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer Kerryn W. RedingJonine L. BernsteinThe WECARE Collaborative Study Group Epidemiology 05 February 2010 Pages: 491 - 498
Methylenetetrahydrofolate reductase polymorphisms and breast cancer risk: a meta-analysis from 41 studies with 16,480 cases and 22,388 controls Xiaowei QiXiangyu MaJun Jiang Epidemiology 05 February 2010 Pages: 499 - 506
Quality of life among women recently diagnosed with invasive breast cancer: the Pathways Study Marilyn L. KwanIsaac Joshua ErgasLawrence H. Kushi Epidemiology 06 February 2010 Pages: 507 - 524
Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the Black Women’s Health Study Edward A. Ruiz-NarvaezLynn RosenbergJulie R. Palmer Epidemiology 07 February 2010 Pages: 525 - 530
Past recreational physical activity, body size, and all-cause mortality following breast cancer diagnosis: results from the breast cancer family registry Theresa H. M. KeeganRoger L. MilneEsther M. John Epidemiology 07 February 2010 Pages: 531 - 542
Lack of association between MnSOD Val16Ala polymorphism and breast cancer risk: a meta-analysis involving 58,448 subjects Li-Xin QiuLei YaoXi-Chun Hu Epidemiology 09 February 2010 Pages: 543 - 547
MTHFR C677T polymorphism associated with breast cancer susceptibility: a meta-analysis involving 15,260 cases and 20,411 controls Jian ZhangLi-Xin QiuXi-Chun Hu Epidemiology 09 February 2010 Pages: 549 - 555
NBS1 8360G > C polymorphism is associated with breast cancer risk: a meta-analysis Zhanwei WangDan CuiWeiquan Lu Epidemiology 09 February 2010 Pages: 557 - 561
TGFB1 L10P polymorphism is associated with breast cancer susceptibility: evidence from a meta-analysis involving 47,817 subjects Li-Xin QiuLei YaoXi-Chun Hu Epidemiology 09 February 2010 Pages: 563 - 567
Extremely low-frequency electromagnetic fields exposure and female breast cancer risk: a meta-analysis based on 24,338 cases and 60,628 controls Chunhai ChenXiangyu MaZhengping Yu Epidemiology 10 February 2010 Pages: 569 - 576
The association between HSD17B1 Ser312Gly polymorphism and breast cancer risk: a meta-analysis including 31,053 subjects Lei YaoLi-huan CaoLong Yu Epidemiology 12 February 2010 Pages: 577 - 580
Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families Zsofia K. StadlerEmmanuel SaloustrosMark E. Robson Brief Report 11 March 2010 Pages: 581 - 585
Identification of a new complex deleterious mutation in exon 18 of the BRCA2 gene in a hereditary male/female breast cancer family Orland DiezSara Gutiérrez-EnríquezGemma Llort Brief Report 16 March 2010 Pages: 587 - 590
Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase Kristy A. BrownNicole I. HungerEvan R. Simpson Brief Report 19 March 2010 Pages: 591 - 596
Among women who experience a recurrence after postmastectomy radiation therapy irradiation is not associated with more aggressive local recurrence or reduced survival Wendy A. WoodwardPauline T. TruongThomas A. Buchholz Brief Report 20 March 2010 Pages: 597 - 605
RAD50 gene mutations are not likely a risk factor for breast cancer in Poland Maria MosorIwona Ziółkowska-SuchanekJerzy Nowak Letter to the Editor 23 June 2010 Pages: 607 - 609
Expression of the stem cell marker ALDH1 in the normal breast of BRCA1 mutation carriers Marise R. Heerma van VossPetra van der GroepPaul J. van Diest Letter to the Editor 29 June 2010 Pages: 611 - 612
